All cancers start with mutated genes. Gene mutations can be inherited or can occur from environmental exposure. Studying genomics, genes, and gene function gives researchers and clinicians insight into how mutated genes impact cancer symptoms, tumor progression, treatment response, and health outcomes.
Munich Leukemia Laboratory in Munich, Germany, leads leukemia diagnostics and research in Europe. Read about how their team improved customer turnaround time and report quality using IDT customized xGen Lockdown Panels.
Next generation sequencing (NGS) is a sequencing method that can provide valuable insight into cancer treatment and prevention. There are several approaches to using this technology for cancer research. Whole genome sequencing provides a comprehensive view of the genetic sequence of the sample, whether it be blood, tissue, or tumor. Targeted next generation sequencing focuses on specific areas of the genome that might be more relevant for cancer. For example, exome sequencing provides insight into protein-coding genes and is especially useful when evaluating mutation load. Hybridization capture panels can be customized to include nonprotein coding genes that might be relevant to a specific cancer like leukemia or breast cancer. NGS can include sequencing DNA or RNA. Because RNA can change the way proteins are expressed, RNA sequencing can also help researchers and clinicians learn more about cancer.
Mirna Jarosz is IDT’s general manager of NGS products and solutions. She's enthusiastic about the ways next generation sequencing technology can enable discoveries in immuno-oncology.
Working in an area that would benefit from sequencing? Just starting? See how you can easily improve your workflows and results.
The xGen Exome Research Panel v2 consists of 415,115 individually synthesized and quality controlled xGen Lockdown Probes. The Exome Research Panel spans a 34 Mb target region (19,433 genes) of the human genome and covers 39 Mb of end-to-end tiled probe space.
The xGen Acute Myeloid Leukemia (AML) Cancer Panel v1.0 comprises 11,731 xGen Lockdown Probes, spanning 1.19 Mb of the human genome, for targeted enrichment of >260 genes associated with AML, to provide more efficient detection of disease-causing mutations.
NGS Discovery Pools allow you to build custom panels quickly at a fraction of the cost of conventional custom panels.
The xGen Inherited Diseases Panel enables deeper sequencing of genomic regions containing genes and SNPs associated with inherited diseases. The gene list is based on the HGMD® (Human Gene Mutation Database) repository of known inherited disease-causing mutations.